65,437 trials
Total Knee Replacement · Virtual Reality Therapy · Osteoarthritis
Primary: Pain: Visual Analogue Scale (VAS) — -23.03; -28.97 units on a scale — p=0.05
Excessive Sleepiness · Parkinson Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation — 1; 2; 0; 0 Participants
Nasal Valve Collapse · Nasal Breathing
Primary: NOSE Responder Rate — 35; 52 Participants — p=0.0001
Psychiatric Disorder
Primary: Attainment of Employment or Education — 128; 74 Participants
Heart Failure
Primary: Lead Complication-free Rate at 6 Months — 97.59 Survival Probability (% of subjects)
Signs and Symptoms, Respiratory · Mobile Applications · Activity Trackers
Primary: Rate of Recruitment — 9; 9; 9 Participants
Head and Neck Cancer · Precancerous Condition
Primary: Overall Survival — 84.6; 77.9 percentage of participants
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 31.87; NA Months — p=<0.0001
Pharmacokinetics · Cancer
Primary: Number of Participants Who Experienced at Least One Adverse Event (AE) — 2; 5; 4; 5 Participants
Cystic Fibrosis
Primary: Change in Weight-for-age Z-score — -0.018; 0.045 Z-score — p=0.2521
Pregnant
Primary: Mean Blood Collection Time — 49; 44 Seconds
Lung Cancer
Primary: Overall Survival (OS) — 7.46; 8.38 Months — p=0.1144
Advanced Malignant Neoplasm · Dermatologic Complication
Primary: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone (Study I) — 0; 0 Participants
Systemic Lupus Erythematosus
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 48; 139 Participants
Migraine Headache
Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-day Period of the 12-week Treatment Phase — -4.2; -3.0 Migraine headache days